Friday November 27 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

Zenyth Therapeutics Limited

Zenyth Therapeutics Limited (Zenyth) is a public listed (ASX: ZTL) Australian biotechnology company primarily focused on the development and commercialisation of antibody-based therapies in the areas of inflammation and cancer. Zenyth has intellectual property rights to a number of key molecules which have pivotal roles in cancer and inflammatory diseases including rheumatoid arthritis and asthma. Zenyth’s scientific team has expertise in antibody generation and engineering and works closely with academic medical research institutes as well as local and international pharmaceutical and biotechnology companies to advance therapies from the discovery phase through to commercialisation. Zenyth’s current corporate partners include Merck and Co., Inc., Cambridge Antibody Technology, MuriGen Therapeutics and Medarex Inc. In addition, Zenyth has an antibody library licence agreement with Dyax Corporation.


Contact Details:
ABN 37 006 614 375576 Swan Street
Richmond
Victoria
3121
Australia
Tel:61 3 9208 4000
Fax:61 3 9208 4350
Email:
WWW:

www.amrad.com.au/




Press Releases on Zenyth Therapeutics Limited:

BioPortfolio Logo
WEHI Spin-Out MuriGen Restructures G-CSF Antagonist Program With CSL 27th October, 2008
MELBOURNE, Australia, October 27 /PRNewswire/ -- MuriGen Therapeutics today announced that its collaboration with CSL for the development of a new class of drugs that target arthritis and other

BioNews Results for Zenyth Therapeutics Limited:

EKR Therapeutics Named Private Company of the Year By New Jersey Technology Council
Pharma Live:  Nov 23 2009 2:58AM Matching: therapeutics
Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group
PR Newswire:  Nov 23 2009 12:48AM Matching: therapeutics
Cornerstone Therapeutics Appoints General Counsel
Pharma Live:  Nov 22 2009 3:01PM Matching: therapeutics
Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of ...
PipelineReview:  Nov 22 2009 12:12AM Matching: therapeutics
Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal
Freshnews.com:  Nov 21 2009 12:41AM Matching: therapeutics
Promote your company here: BioNewsCast - Press Release Distribution

View more Zenyth Therapeutics Limited news.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 591 times since April 2007, the link to the organisation's website has been followed 99 times

Recent Search Terms used to find this page: zenyth therapeutics | merk zenyth deal | zenyth therapeutics | zenyth therapeutics | Merck Co and Zenyth Therapeutics | zenyth richmond | zenyth richmond | drugs developed by zenyth | Zenyth | Zenyth Therapeutics Limited | .

Search for more companies in Richmond

Search for more companies in Victoria



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Zenyth Therapeutics Limited

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.